AAD Guidelines- Focused Update: Guidelines of care for the management of atopic dermatitis in adults
Description
Background: In 2023 and 2024, the AAD published guidelines on the use of topical and systemic therapies for the management of atopic dermatitis (AD) in adults. Since the publication of these guidelines, several novel therapies have emerged to treat AD. Objective: To update previous guidelines on the management of AD in adults by providing evidence-based recommendations on the use of additional FDA-approved topical and systemic therapies. Methods: A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations. Results: The workgroup developed four new recommendations for the management of AD in adults. Limitations: This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of the considered therapies for AD are of short duration, limiting comparative long-term efficacy and safety conclusions.
Files
Steps to reproduce
A multidisciplinary workgroup conducted a systematic review and applied the GRADE approach for assessing the certainty of evidence and formulating and grading recommendations.